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Summary
Background The MTHFR 677C→T polymorphism has been associated with raised homocysteine concentration and 
increased risk of stroke. A previous overview showed that the eﬀ ects were greatest in regions with low dietary folate 
consumption, but diﬀ erentiation between the eﬀ ect of folate and small-study bias was diﬃ  cult. A meta-analysis of 
randomised trials of homocysteine-lowering interventions showed no reduction in coronary heart disease events or 
stroke, but the trials were generally set in populations with high folate consumption. We aimed to reduce the eﬀ ect of 
small-study bias and investigate whether folate status modiﬁ es the association between MTHFR 677C→T and stroke 
in a genetic analysis and meta-analysis of randomised controlled trials.
Methods We established a collaboration of genetic studies consisting of 237 datasets including 59 995 individuals with 
data for homocysteine and 20 885 stroke events. We compared the genetic ﬁ ndings with a meta-analysis of 
13 randomised trials of homocysteine-lowering treatments and stroke risk (45 549 individuals, 2314 stroke events, 
269 transient ischaemic attacks).
Findings The eﬀ ect of the MTHFR 677C→T variant on homocysteine concentration was larger in low folate regions 
(Asia; diﬀ erence between individuals with TT versus CC genotype, 3·12 μmol/L, 95% CI 2·23 to 4·01) than in areas 
with folate fortiﬁ cation (America, Australia, and New Zealand, high; 0·13 μmol/L, –0·85 to 1·11). The odds ratio (OR) 
for stroke was also higher in Asia (1·68, 95% CI 1·44 to 1·97) than in America, Australia, and New Zealand, high (1·03, 
0·84 to 1·25). Most randomised trials took place in regions with high or increasing population folate concentrations. 
The summary relative risk (RR) of stroke in trials of homocysteine-lowering interventions (0·94, 95% CI 0·85 to 1·04) 
was similar to that predicted for the same extent of homocysteine reduction in large genetic studies in populations 
with similar folate status (predicted RR 1·00, 95% CI 0·90 to 1·11). Although the predicted eﬀ ect of homocysteine 
reduction from large genetic studies in low folate regions (Asia) was larger (RR 0·78, 95% CI 0·68 to 0·90), no trial has 
evaluated the eﬀ ect of lowering of homocysteine on stroke risk exclusively in a low folate region.
Interpretation In regions with increasing levels or established policies of population folate supplementation, evidence 
from genetic studies and randomised trials is concordant in suggesting an absence of beneﬁ t from lowering of 
homocysteine for prevention of stroke. Further large-scale genetic studies of the association between MTHFR 677C→T 
and stroke in low folate settings are needed to distinguish eﬀ ect modiﬁ cation by folate from small-study bias. If future 
randomised trials of homocysteine-lowering interventions for stroke prevention are undertaken, they should take 
place in regions with low folate consumption.
Funding Full funding sources listed at end of paper (see Acknowledgments).
Introduction
Prospective cohort studies previously estimated that, if 
causal, a reduction of 3 μmol/L in serum homocysteine 
would decrease risk of coronary heart disease by 18% 
and stroke by 24% after a mean follow-up of 7·3 years.1,2 
However, residual confounding and reverse causation 
are alternative non-causal explanations for the 
observational association.3,4 Mendelian randomisation 
studies use genetic variants as proxies of non-genetic 
risk factors to assess whether a risk factor is causally 
related to a disease. The approach exploits the 
independent randomised assortment of maternal and 
paternal alleles at the time of gamete formation to 
reduce confounding, and the ﬁ xed nature of genotype to 
abolish reverse causality and minimise regression-
dilution bias, which can aﬀ ect the association of a 
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non-genetic risk factor with disease.5–7 Mendelian 
randomisation analyses have previously investigated the 
potential causal role of homocysteine in stroke1 and 
coronary heart disease8,9 using the MTHFR 677C→T 
variant (rs1801133) as a proxy for homocysteine 
concentration that is independent of other risk factors, 
and have provided support for a causal role of 
homocysteine in stroke.1,10 However, literature-based 
genetic meta-analyses can be aﬀ ected by small-study 
bias.9 For instance, in our previous mendelian 
randomisation analysis of MTHFR 677C→T,10 only two 
studies had more than 400 stroke cases.
In addition to our original study, results of other 
studies11–13 also suggest that the eﬀ ect of the 
MTHFR 677C→T variant on homocysteine concen-
tration could be modiﬁ ed by the prevailing 
concentrations of folic acid, with high folate being 
associated with a reduced eﬀ ect of MTHFR 677C→T on 
homocysteine concentrations. This suggestion is 
further supported by evidence that low folate intake or 
concentrations are associated with increased stroke 
risk.14 This gene–environment interaction is biologically 
plausible because folic acid plays a central part in the 
metabolism of homocysteine. Similarly, eﬀ ect 
modiﬁ cation of folic acid on the MTHFR 677C→T eﬀ ect 
has also been suggested for colon cancer.15 If prevailing 
concentrations of folic acid do modify homocysteine 
concentration, established policies for folic acid 
fortiﬁ cation of cereals and ﬂ our in several countries, for 
the prevention of neural tube defects,16 would also be 
expected to modify the association between 
MTHFR 677C→T and stroke risk. This eﬀ ect would 
also modify the interpretation of published randomised 
clinical trials of homocysteine-lowering interventions 
for stroke prevention that have shown no reduction in 
stroke risk in meta-analysis,17 but trials to date have 
been predominantly set in populations with high 
folate consumption.
To investigate the potential modifying eﬀ ect of folate 
status on the association between the MTHFR 677C→T 
variant and stroke risk, we established a collaboration of 
genetic studies including data for homocysteine 
concentration and stroke events. We compared the 
ﬁ ndings of this updated genetic analysis with a meta-
analysis of randomised controlled trials of homocysteine-
lowering treatments on stroke risk.
Methods
Search strategy and selection criteria
Webappendix pp 1–7 provides detailed information about 
methods used. We did a literature search in Medline up 
to August, 2010, to identify randomised controlled trials 
using homocysteine-lowering interventions that evalu-
ated cardiovascular endpoints. Medline and Embase were 
searched up to January, 2008, for all studies of the 
association between the rs1801133 polymorphism 
(MTHFR 677C→T variant) and stroke. To minimise 
reporting and publication bias, we supplemented our 
database with unpublished data by contacting investi-
gators who reported genetic ﬁ ndings in stroke or 
cardiovascular disease in peer-reviewed journals.
Data extraction
Data were extracted and entered into a database for 
randomised trials (MVH and JPC) and genetic studies 
(PN, MVH). Genetic studies were classiﬁ ed into ﬁ ve 
categories of probable folate status. Full details of this 
process (developed and validated by Robert Clarke, 
Clinical Trial Service Unit and Epidemiological Studies 
Unit, University of Oxford, UK) are provided on 
webappendix pp 1–7. In brief, Robert Clarke undertook 
a systematic review of population-based studies in 
adults that measured folic acid concentration or 
quantiﬁ ed folate intake from nutritional question-
naires. Information about geographical location of 
study, years of conduct, and regional folic acid 
fortiﬁ cation policies (including years in which policies 
were established, if relevant) were used to generate ﬁ ve 
categories approximating the probable folate status at 
the population level. Categories were sorted from lowest 
to highest probable folate status: (1) no fortiﬁ cation 
(Asia, north and sub-Saharan Africa); (2) low 
(prefortiﬁ cation in 1996: Europe, including Ireland, 
Scandinavia, the Netherlands, Russia, and Turkey); 
(3) mid (post fortiﬁ cation in 1996: Europe); (4) mid 
(prefortiﬁ cation: America, Australia, and New Zealand 
before 1996; Central and South America); (5) high 
postfortiﬁ cation (America, Australia, and New Zealand 
after 1996, Chile after 2000).
Statistical analysis
Statistical analysis followed guidelines from the HuGE 
Review Handbook for meta-analysis of genetic association 
studies18 and the Cochrane Handbook for Systematic 
Reviews of Interventions.19 In all meta-analyses, the 
presence of small-study bias was investigated by funnel 
plot and Egger test.20 Additionally, we attempted to 
quantify the potential eﬀ ect of small-study bias by 
restricting the analysis to large studies only, using the 
trim-and-ﬁ ll method,21 and estimating the number of 
null hypothetical studies that were needed to add to 
change the summary eﬀ ect from the meta-analysis (see 
webappendix pp 1–7 for further details).
Random eﬀ ect models (DerSimonian and Laird) were 
used to obtain the mean diﬀ erence in concentrations of 
homocysteine according to MTHFR 677C→T genotype 
(CC, homozygous common allele; CT, heterozygous; and 
TT, homozygous rare allele). Individuals homozygous for 
the C allele were used as the reference group. We did an 
ad-hoc analysis to investigate whether diﬀ erences in 
plasma folate by the MTHFR 677C→T variant were also 
modiﬁ ed by folate status category.
We did a meta-analysis of published and unpublished 
genetic studies on stroke to obtain a per-genotype 
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summary odds ratio (OR) and corresponding 95% CI 
(using random eﬀ ect models, DerSimonian and Laird) 
for all stroke types combined, using individuals homo-
zygous for the C allele as the reference group.
To check for confounding, we used Genome-wide 
Linkage Disequilibrium Repository and Search engine 
(GLIDERS) software22 to evaluate long-range linkage 
disequilibrium for the rs1801133 variant in diﬀ erent 
ethnic groups. We crosschecked retrieved single 
nucleotide polymorphisms (SNPs) in genome-wide 
association study repositories (NHGRI GWAS Catalog23 
and SNPnexus) to conﬁ rm or refute whether any of these 
variants were associated with stroke or a stroke-related 
trait (eg, blood pressure).
Finally, we did a meta-analysis of randomised trials to 
estimate the eﬀ ect of homocysteine-lowering treat ment 
(ie, folic acid supplementation with or without additional 
B vitamins) on stroke risk in trials using placebo, low 
dose-folic acid, or usual care as the comparator group. We 
used the DerSimonian and Laird Q test in all meta-
analyses to evaluate the degree of heterogeneity between 
studies, and the I² measure to describe the proportion 
of total variation in study estimates attributable to 
heterogeneity.24
Role of the funding source
The funding sources had no role in study design, in the 
collection, analysis, and interpretation of data, in writing 
of the report, or in the decision to submit for publication. 
The corresponding author (JPC) had full access to all data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Number of individuals Number of individuals
TT                      CC CT                      CC
Mean diﬀerence
(95% CI)
Mean diﬀerence
(95% CI)
All studies
Asia
Europe, low
Europe, mid
AANZ, mid
AANZ, high
Large studies
Asia
Europe, low
Europe, mid
AANZ, high
1076
1077
1029
261
2859
690
972
399
2773
2377
6169
3421
518
11 569
1321
5712
1507
11 229
3·12 (2·23 to 4·01)
2·27 (1·55 to 3·00)
2·10 (1·53 to 2·67)
1·52 (0·68 to 2·35)
0·13 (–0·85 to 1·11)
3·77 (2·76 to 4·78)
2·80 (1·94 to 3·65)
2·17 (1·67 to 2·68)
1·40 (1·16 to 1·64)
2900
5055
3569
529
11 234
1741
4665
1588
10 966
2377
6169
3421
518
11 569
1321
5712
1507
11 229
0·83 (0·45 to 1·21)
0·34 (0·13 to 0·56)
0·36 (0·12 to 0·61)
0·22 (–0·26 to 0·70)
0·32 (0·12 to 0·51)
0·38 (0·07 to 0·69)
0·46 (0·30 to 0·62)
0·34 (0·03 to 0·65)
0·30 (0·18 to 0·42)
0–1 1·5 3 5
A    MTHFR TT versus CC B    MTHFR CT versus CC
Concentration of homocysteine (μmol/L)
HigherLower
0–1 0·3 0·9 1·3
Concentration of homocysteine (μmol/L)
HigherLower
Figure 1: Diﬀ erence in homocysteine concentration in individuals without cardiovascular disease according to MTHFR 677C→T genotype, by probable folate 
status category
Large studies are those with more than 500 individuals. AANZ=America, Australia, and New Zealand.
Odds ratio (95% CI)
Asia
(41 datasets, 8150 stroke cases)
Europe, low
(15 datasets, 3776 stroke cases)
Europe, mid
(37 datasets, 6597 stroke cases)
AANZ, mid
(4 datasets, 398 stroke cases)
AANZ, high
(5 datasets, 1964 stroke cases)
1·68 (1·44 to 1·97)
1·01 (0·88 to 1·16)
1·33 (1·14 to 1·55)
1·42 (0·89 to 2·27)
1·03 (0·84 to 1·25)
Odds ratio (95% CI)
1·30 (1·17 to 1·45)
1·01 (0·93 to 1·09)
1·14 (1·03 to 1·25)
0·70 (0·46 to 1·05)
1·05 (0·91 to 1·22)
B    MTHFR CT versus CCA    MTHFR TT versus CC
10·80·6 1·4 2
Higher riskLower risk
10·80·6 1·4 2
Higher riskLower risk
Figure 2: Odds ratio of stroke according to MTHFR 677C→T variant, by probable folate status category
Left panel compares individuals homozygous for T allele with CC participants. Right panel compares heterozygous with CC individuals. AANZ=America, Australia, and 
New Zealand.
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Results
We established a collaboration of genetic studies 
consisting of 237 datasets, including 59 995 individuals 
with data for homocysteine and 20 885 stroke events. For 
analysis of homocysteine and the MTHFR 677C→T 
polymorphism, 98 datasets from 79 studies, including 
59 995 individuals, met our selection criteria. 67 datasets 
(webappendix pp 18–19) including 53 643 participants 
without evidence of cardiovascular disease contributed to 
the analysis of the association between MTHFR 677C→T 
and homocysteine concentration. A histogram of sample 
sizes (webappendix p 8) and genotype frequencies 
according to folate status category and by ethnic group 
(webappendix p 9–10) are provided. Individuals from the 
remaining 31 datasets (of 98) were excluded because they 
had cardiovascular disease, which could aﬀ ect the derived 
value of the gene variant on homocysteine concen-
trations.10 In individuals without cardiovascular disease, 
irrespective of probable folate status, the mean diﬀ erence 
in homocysteine concentrations between those homo-
zygous for the T allele compared with those homozygous 
for the C allele was 2·10 μmol/L (95% CI 1·71 to 2·50; 
I²=83·5%). For heterozygous individuals, the mean 
diﬀ erence in homocysteine concentration was 
0·42 μmol/L (95% CI 0·30 to 0·54; I²=49·3%) compared 
with those with the CC genotype.
The MTHFR 677C→T eﬀ ect on homocysteine was 
highly dependent on probable folate status category 
(ﬁ gure 1). In regions with no supplementation with folic 
acid (Asia), participants homozygous for the T allele had 
higher concentrations of homocysteine (3·12 μmol/L, 
95% CI 2·23 to 4·01) than did those homozygous for the 
C allele. The eﬀ ect was reduced in studies undertaken in 
geographical regions with policies of folic acid fortiﬁ cation 
(America, Australia, and New Zealand, high: 0·13 μmol/L, 
95% CI –0·85 to 1·11). When analysis was limited to 
large studies (≥500 individuals), similar results were 
obtained (ﬁ gure 1). Patterns were similar when 
heterozygous individuals were compared with those 
homozygous for the C allele, although the magnitude of 
the genetic eﬀ ect was smaller (ﬁ gure 1).
A metaregression analysis showed an inverse associ-
ation between diﬀ erence in homocysteine concentration 
by genotype (TT vs CC) and probable folate status category 
coded in ascending order of probable levels of folic acid 
status (Asia; Europe, low; Europe, mid; America, 
Australia, and New Zealand, mid; and America, Australia, 
and New Zealand, high), suggesting an interaction 
between MTHFR 677C→T variant and folate status. For a 
one-category increase in folate status, the genetic eﬀ ect 
on homocysteine concentration was reduced by 
0·62 μmol/L (95% CI 0·29 to 0·94). To explore possible 
eﬀ ects of small-study bias, metaregression was restricted 
to only large studies (≥500 individuals) and a similar 
pattern was noted (β coeﬃ  cient for a one-category 
increase was equal to a reduction in homocysteine of 
0·54 μmol/L, 95% CI 0·05 to 1·03). In a subset of 
35 studies totalling 12 007 participants with information 
about plasma folic acid concentration, metaregression 
analysis suggested that for every increase of 1 ng/mL in 
plasma folic acid concentration, the mean diﬀ erence in 
homocysteine concentrations for TT individuals versus 
CC individuals decreased by 0·13 μmol/L (95% CI 
–0·01 to 0·28). The Egger regression test (which tests the 
A
B
Number cases Odds ratio (95% CI)
Asia 3·77 μmol/L (95% CI 2·76 to 4·78)
Somarajan26
Li27
Yamada28
Li29
Subtotal
422
454
636
1823
3335
1·21 (0·43 to 3·42)
1·77 (0·95 to 3·29)
1·36 (1·04 to 1·79)
1·21 (1·01 to 1·45)
1·28 (1·11 to 1·48)
0·87 (0·59 to 1·28)
1·16 (0·86 to 1·56)
1·20 (1·03 to 1·40)
1·14 (0·99 to 1·32)
422
454
1823
3335
Asia 0·38 μmol/L (95% CI 0·07 to 0·69)
Somarajan26
Li27
Li29
Subtotal
Europe, low 2·80 μmol/L (95% CI 1·94 to 3·65)
Hofman30
Frederiksen31
Kostulas32
Frederiksen31
Subtotal
454
498
600
836
2388
1·11 (0·79 to 1·52)
1·13 (0·81 to 1·55)
0·73 (0·48 to 1·10)
0·99 (0·76 to 1·28)
1·00 (0·85 to 1·18)
1·01 (0·83 to 1·23)
1·09 (0·90 to 1·32)
0·92 (0·71 to 1·18)
0·96 (0·83 to 1·12)
1·00 (0·91 to 1·09)
454
498
600
836
2388
Europe, low 0·46 μmol/L (95% CI 0·30 to 0·62)
Hofman30
Frederiksen31
Kostulas32
Frederiksen31
Subtotal
Europe, mid 2·17 μmol/L (95% CI 1·67 to 2·68)
Szolnoki33
Lalouschek34
Day35
Szolnoki36
Subtotal
407
450
654
867
2378
1·39 (0·80 to 2·41)
0·80 (0·53 to 1·20)
0·98 (0·75 to 1·27)
1·19 (0·87 to 1·62)
1·04 (0·85 to 1·26)
AANZ, high 1·40 μmol/L (95% CI 1·16 to 1·64)
Meschia37, 38 1069 0·94 (0·72 to 1·21)
1·20 (0·87 to 1·65)
0·92 (0·72 to 1·17)
1·06 (0·90 to 1·25)
1·17 (0·95 to 1·45)
1·07 (0·96 to 1·19)
407
450
654
867
2378
Europe, mid 0·34 μmol/L (95% CI 0·03 to 0·65)
Szolnoki33
Lalouschek34
Day35
Szolnoki36
Subtotal
1·08 (0·91 to 1·27)1069
AANZ, high 0·30 μmol/L (95% CI 0·18 to 0·42)
Meschia37, 38
MTHFR TT versus CC
MTHFR CT versus CC
0·4 1 2 4
Lower risk Higher risk
Figure 3: Odds ratio of stroke in large studies (≥400 stroke events) according to MTHFR 677C→T genotype, 
by probable folate status category
Diﬀ erences in homocysteine concentration (derived from large studies; ﬁ gure 1) are shown in category 
subheadings.
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null hypothesis that the funnel plot is symmetrical20) 
coeﬃ  cient was 0·79 (95% CI –0·10 to 1·69; p=0·08) for 
TT versus CC comparison, and 0·36 (95% CI 
–0·14 to 0·87; p=0·16) for the CT versus CC comparison 
(including all studies, irrespective of geographical 
location). By contrast with a clear eﬀ ect of folate status 
category on the MTHFR–homocysteine association, the 
evidence from our subsample of studies with data for 
plasma folic acid concentration did not reveal a clear 
trend between MTHFR and plasma folic acid across 
probable folate categories (data not shown).
140 datasets from 101 studies including 20 885 stroke 
events met our selection criteria and were included in the 
meta-analysis of MTHFR 677C→T polymorphism and 
stroke (webappendix pp 20–21). 94 datasets measured 
ischaemic stroke (17 909 cases), 20 haemorrhagic stroke 
(1615 cases), one silent brain infarction (161 cases), and 
25 total stroke (6972 cases, including ischaemic and 
haemorrhagic cases, resulting in overlap between 
categories). Total stroke included studies that reported 
both haemorrhagic and ischaemic stroke and those that 
did not classify stroke because neuroimaging was 
unavailable. Of the studies that did not classify stroke, 
17 were in individuals of European ancestry in whom 
most strokes are of ischaemic cause. Genotype 
frequencies according to folate status category and by 
ethnic origin are reported on webappendix p 11–12.
The summary OR for the main stroke comparison 
irrespective of probable folate status category was 1·37 
(95% CI 1·25 to 1·50; I²=48·4%) for participants 
homozygous for the T allele compared with those 
homozygous for the C allele (webappendix p 13). The OR 
for heterozygous individuals was 1·14 (95% CI 
1·08 to 1·21; I²=43·4%). When restricted to large studies 
(≥400 stroke events), the OR was 1·09 (95% CI 
0·98 to 1·20; I²=24·6%) for TT individuals and 1·06 
(95% CI 1·00 to 1·12; I²=0·0%) for CT individuals 
compared with those homozygous for the C allele. 
Results for diﬀ erent stroke subtypes followed a similar 
pattern (webappendix p 13).
In regions without folic acid fortiﬁ cation (Asia),25 the 
odds of stroke was 1·68 (95% CI 1·44 to 1·97) for 
Summary of genetic studies (limited to large studies, ≥400 stroke events)
Asian population
Non-Asian population
Summary
RCTs of homocysteine-lowering interventions, by regional folate supplementation
Europe, low
Liem (1998–2002)42
Ebbing (1999–2006)43
Bonaa (1998–2002)44
Subtotal
Europe, mid
Righetti (2001–05)45
SEARCH (1998–2005)46
Subtotal
Mixed
50% Asia, 32% Europe mid, 15% AANZ high
VITATOPS (1998–2009)47
72% AANZ high, 28% Europe mid
HOPE-2 (2000–05)48
Subtotal
AANZ, high
House (2001–07)49
Zoungas (1998–2003)50
Wrone (1998–2000)51
Jamison (2001–03)52
Albert (1998–2005)53
Toole (1996–2003)54
Subtotal
Summary
3·8
2·4
2·6
2·6 (0·22)
3·0 (0·27)
3·8 (0·28)
3·4 (0·27)
15·1 (0·44)
3·7 (0·28)
3·8 (0·28)
4·0 (0·28)
3·2 (0·26)
3·7 (0·27)
4·8 (0·31)
1·9 (0·08)
3·6 (0·11)
5·4 (0·25)
1·6 (0·13)
1·9 (0·14)
2·5 (0·16)
3·3 (0·24)
3335
5835
9170
20
67
98
185
3
534
537
748
258
1006
7
26
27
78
148
300
586
2314
Homocysteine
reduction, μmol/L (%)
Number of
strokes
Relative risk
(95% CI)
0·78 (0·68 to 0·90)
1·00 (0·90 to 1·11)
0·92 (0·83 to 1·02)
0·65 (0·27 to 1·57)
0·72 (0·45 to 1·17)
1·00 (0·68 to 1·48)
0·85 (0·64 to 1·13)
0·69 (0·06 to 7·32)
1·01 (0·86 to 1·20)
1·01 (0·86 to 1·20)
0·92 (0·81 to 1·06)
0·76 (0·59 to 0·96)
0·86 (0·71 to 1·04)
5·81 (0·71 to 47·59)
0·45 (0·20 to 1·01)
1·20 (0·53 to 2·68)
0·90 (0·58 to 1·38)
1·14 (0·83 to 1·57)
1·04 (0·84 to 1·29)
1·01 (0·79 to 1·28)
0·94 (0·85 to 1·04)
0·2 0·4
Homocysteine-lowering better Comparator better
0·8 1 1·5 2
Figure 4: Pooled relative risk of stroke from randomised clinical trials of homocysteine-lowering interventions in the context of genetic studies of the MTFHR 677C→T variant
RCT=randomised controlled trials. AANZ=America, Australia, and New Zealand.
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comparison of individuals with the TT genotype and 
those with the CC genotype (ﬁ gure 2). This increase in 
risk was substantially larger than that noted in regions 
with low folate intake (Europe, low: OR 1·01, 95% CI 
0·88 to 1·16) and regions with mid folate intake (Europe, 
mid: OR 1·33, 95% CI 1·14 to 1·55) or folate fortiﬁ cation 
(America, Australia, and New Zealand, high: OR 1·03, 
95% CI 0·84 to 1·25). A similar pattern was reported in 
comparisons of heterozygous (CT) individuals and those 
with the CC genotype (ﬁ gure 2).
To examine the eﬀ ect of small-study bias on the 
association between MTHFR TT versus CC in Asia and 
risk of stroke, we ﬁ rst restricted our analysis to studies 
with 400 or more stroke events, which yielded an OR 
of 1·28 (95% CI 1·11 to 1·48; ﬁ gure 3).26–38 We then did a 
trim-and-ﬁ ll analysis that, after taking into consider-
ation the number and outcomes of potentially missing 
data, provided an adjusted summary OR equal to 1·30 
(95% CI 1·19 to 1·43; webappendix p 14), which was 
concordant with the point estimate derived from our 
analysis restricted to large studies. Last, we undertook a 
sensitivity analysis to estimate the eﬀ ect on the point 
estimate of the OR for stroke risk in Asian studies (for 
the MTHFR TT vs CC comparison) from the sequential 
addition of hypothetical large and null studies of 
400 stroke cases and 400 controls with equal distribution 
according to expected MTHFR C/T genotype frequencies 
in Asian ancestry (webappendix pp 4–5). We estimated 
that 41 such studies would be needed to reduce the 
overall point estimate from OR 1·68 to 1·15 (the 
threshold at which cumulative evidence in genetic 
studies would be downgraded on the basis of Venice 
criteria39) and 260 such studies to reduce the lower 
bound of the 95% CI to 1·00; other hypothetical 
scenarios are reported on webappendix p 22. Further-
more, genetic studies of MTHFR and stroke from Asia 
contributed as many stroke cases as did other 
geographical regions, with no major diﬀ erences in the 
mean allele frequency for the MTHFR C/T variant 
(webappendix pp 9–12).
A metaregression analysis showed that for a shift from 
one folate status category to the next highest category, the 
OR for stroke decreased by 10% (95% CI 1 to 18) for the 
TT versus CC comparison and 6% (95% CI 1 to 12) for 
the CT versus CC comparison. In a subsample of 
25 studies (6266 stroke events) with information about 
both stroke and homocysteine concentration, the OR for 
the TT versus CC genotype tended to increase as the 
diﬀ erence in homocysteine concentration by genotype 
increased: from 1·28 (95% CI 0·96 to 1·71) for studies 
with the smallest diﬀ erence in homocysteine (bottom 
tertile) to 1·67 (95% CI 1·18 to 2·35) in studies with the 
largest diﬀ erence in homocysteine (top tertile). However, 
there was substantial overlap in the conﬁ dence intervals 
by category and the metaregression analysis p value 
was 0·34. No trend was noted for heterozygous 
individuals (webappendix p 15).
When we included all studies, the coeﬃ  cient for the 
Egger test was 1·15 (95% CI 0·65 to 1·64; p<0·0001) for TT 
versus CC and 0·90 (95% CI 0·37 to 1·42) for CT versus 
CC (p=0·001). Since this ﬁ nding could be attributable to 
diﬀ erences in the genotypic eﬀ ect by folate categories 
(suggested in ﬁ gure 1 and ﬁ gure 3), we ran the Egger test 
in studies from each geographical region separately. The 
Sample size*
RCT ≥1000 participants
RCT <1000 participants
Risk of bias†
RCT all low-risk
RCT any or high risk
Types of outcome‡
RCT stroke only
RCT stroke plus TIA
Types of comparator§
RCT with placebo or standard care only
RCT with B vitamins and/or placebo
RCT with low-dose folic acid
2231 (8)
83 (5)
1972 (7)
342 (6)
2006 (9)
577 (4)
1822 (9)
165 (2)
327 (2)
7·9
38·7
26·1
21·6
20·5
0
21·7
7·7
0
0·95 (0·87 to 1·03)
0·83 (0·44 to 1·58)
0·95 (0·85 to 1·07)
0·85 (0·66 to 1·11)
0·97 (0·87 to 1·08)
0·91 (0·77 to 1·06)
0·94 (0·85 to 1·05)
0·88 (0·64 to 1·20)
1·07 (0·87 to 1·31)
0·6 0·8 1 1·2 1·4
I² (%)Number of 
clinical events 
(number of RCTs)
Relative risk 
(95% CI)
Comparator betterHomocysteine-lowering better
Figure 5: Sensitivity analyses of eﬀ ect of homocysteine-lowering interventions from randomised clinical trials on risk of stroke
All analyses are random eﬀ ects (DerSimonian and Laird). Number of clinical events reports stroke only as default and stroke plus TIA when speciﬁ ed in row title. 
RCT=randomised controlled trial. TIA=transient ischaemic attack. *Studies with fewer than 1000 participants were Wrone,51 Zoungas,50 Liem,42 Righetti,45 and House.49 
†See webappendix p 24 for classiﬁ cation of risk of bias per study. ‡Studies reporting stroke and TIA separately were Righetti,45 Wrone,51 and HOPE-2.48 §Studies that 
used B vitamins (other than folic acid) as one of the comparator groups were Ebbing43 and Bonaa;44 studies that used low-dose folic acid as comparator group (and 
not  placebo or standard care) were Wrone51 and Toole.54
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respective coeﬃ  cients for the Egger test were (for TT vs 
CC comparisons) 1·20 (95% CI 0·48 to 1·92; p=0·002) for 
Asia; 0·51 (95% CI –0·55 to 1·57; p=0·318) for Europe, 
low; 1·08 (95% CI 0·02 to 2·15; p=0·046) for Europe, mid; 
2·91 (95% CI –2·42 to 8·24; p=0·143) for America, 
Australia, and New Zealand, mid; and 1·29 (95% CI 
–1·59 to 4·17; p=0·250) for America,  Australia, and 
New Zealand, high.
Apart from being a signal in genome-wide association 
studies for homocysteine,40 we did not ﬁ nd reports of an 
association of the rs1801133 (MTHFR 677T) variant with 
established risk factors for stroke, or for any SNPs in 
linkage disequilibrium with it (deﬁ ned as r²>0·3) 
(webappendix p 23). Although one SNP in MTHFR 
(rs17367504) was identiﬁ ed as a genome-wide association 
study locus for systolic blood pressure,41 the linkage 
disequilibrium between rs17367504 and rs1801133 is low 
(r² 0·09 European and Asian, 0·01 African ancestry; 
1000 Genomes Project Pilot 1) and is unlikely to account 
for the association between rs1801133 and stroke.
13 randomised trials of homocysteine-lowering inter-
ventions including 45 549 individuals (2314 stroke events 
and 269 transient ischaemic attacks) met our selection 
criteria for analysis of MTHFR 677C→T and stroke in the 
context of randomised trials of homocysteine-lowering 
interventions (webappendix p 24).42–54 Trials identiﬁ ed 
included mainly participants with vascular disease 
(coronary heart disease or stroke), chronic kidney disease, 
or diabetes. We identiﬁ ed no trials exclusively set in low 
folate regions (Asia) that fulﬁ lled our selection criteria. 
The main outcome for analysis consisted of both fatal 
and non-fatal ischaemic or haemorrhagic stroke and 
the weighted mean follow-up duration was 4·7 years 
(range 2–7·3 years).
Active treatment resulted in a mean reduction in 
homocysteine concentration of 3·33 μmol/L (24% pro-
portionate reduction) and a relative risk of stroke of 0·94 
(95% CI 0·85 to 1·04; I²=18·8%; ﬁ gure 4). Metaregres-
sion analyses of the log of the relative risk for stroke 
against the mean net or proportional reduction in 
homocysteine achieved by the intervention, or against 
the probable folate status category, did not show an 
association (p>0·5). With the probable exception of 
HOPE-2,48 no trial had an undue eﬀ ect on the estimate of 
the pooled relative risk (webappendix p 16). A subgroup 
analysis did not reveal major diﬀ erences of the 
intervention on stroke by prespeciﬁ ed study-level 
characteristic, with the possible exceptions of sample size 
and risk of bias (ﬁ gure 5).
When we compared the eﬀ ect from randomised trials 
undertaken in non-Asian populations to the eﬀ ect of 
large genetic studies in the same population, a 
concordance of no reduction in risk of stroke was noted: 
relative risk reduction 6% (95% CI –4 to 15) and 0% 
(95% CI –11 to 10), respectively (ﬁ gure 4). The relative 
risk reduction suggested by large Asian genetic studies 
of 22% (95% CI 10–32) could not be directly compared 
with interventional trials because no randomised trial 
has been done exclusively in these regions.
Discussion
The MTHFR 677C→T variant was associated with a 
larger eﬀ ect on homocysteine concentration in regions of 
low folate consumption than in regions with high dietary 
folate intake or with established programmes of folic acid 
fortiﬁ cation of ﬂ our for prevention of neural tube defects. 
A similar pattern was noted for the genetic association 
with stroke risk. However, even though our analysis is 
less likely to be aﬀ ected by small-study bias than was our 
previous meta-analysis,10 whether this diﬀ erence reﬂ ects 
modiﬁ cation of the genetic association with stroke risk 
by population folate consumption or small-study bias 
remains unclear (panel).
Even if the evidence of an increased risk of stroke 
associated with the MTHFR 677C→T variant is robust, 
reduction of homocysteine concentration might not 
necessarily reverse the risk of stroke in adult life. Such 
evidence can only be derived from randomised trials of 
interventions such as folic acid that reduce the 
concentration of homocysteine. Our meta-analysis of 
randomised trials evaluating homocysteine-lowering 
treatments in stroke showed a non-signiﬁ cant reduction 
in the risk of stroke of 6% (95% CI –4 to 15). We note, 
however, that with the exception of half the participants 
from the VITATOPS trial who were recruited from low 
folate regions (Asia), the rest of the participants (n=41 467, 
91%) included in trials to date were from regions with 
high concentrations of folic acid or with established 
policies of folic acid fortiﬁ cation. The point estimate 
derived from the randomised trials was, however, 
concordant with that predicted from large genetic studies 
(≥400 stroke events) undertaken outside Asia (0% risk 
reduction; 95% CI –11 to 10; ﬁ gure 4). The concordance 
of results, showing no beneﬁ t on stroke prevention from 
randomised trials and large genetic studies in non-Asian 
populations, suggests that homocysteine-lowering 
treatments in populations already fortiﬁ ed or with 
increasing population levels of folic acid might not 
provide additional beneﬁ t in reduction of the risk of 
stroke. Similar triangulation of genetic studies and 
randomised trials undertaken in low folate regions was 
hampered by the scarcity of evidence from randomised 
trials set in such regions (only 9% of all randomised trial 
participants). Nonetheless, the predicted risk reduction 
in stroke of 22% (95% CI 10 to 32) derived from large 
genetic studies in low folate regions suggests that if an 
adequately powered randomised trial were to be done in 
Asia, homocysteine reduction might have a substantial 
protective eﬀ ect on stroke. However, our data also suggest 
that we cannot reliably exclude that the eﬀ ect of the 
MTHFR 677C→T variant on stroke reported in large 
genetic studies done in low folate regions is attributable 
to other mechanisms diﬀ erent from lowering of 
homocysteine, or to small-study bias.
Articles
www.thelancet.com   Vol 378   August 13, 2011 591
By contrast with our genetic meta-analyses, the estimate 
from randomised trials did not seem to be aﬀ ected by the 
reduction in homocysteine achieved or by probable folate 
status of the population studied. However, this analysis 
was based on study-level characteristics, and thus the 
power to detect real diﬀ erences with only 13 studies (as 
opposed to 101 genetic studies) was restricted, and the 
proportional reduction of homocysteine concentrations 
for most trials was fairly similar (median 26%, 
range 8–31), with the exception of one very small trial45 
that achieved a 44% reduction. Nonetheless, a previous 
meta-analysis55 of homocysteine reduction and vascular 
events found no evidence of heterogeneity when 
stratifying by pretreatment or percentage reduction of 
plasma homocysteine or by regional folate fortiﬁ cation. 
Furthermore, the VITATOPS trial47 did not ﬁ nd evidence 
that individuals of Asian origin had a diﬀ erent eﬀ ect 
from homocysteine reduction than did other individuals.
A few diﬀ erences between the evidence obtained from 
randomised trials and genetic studies are important to 
emphasise. First, as already mentioned, most trial 
evidence arose from settings in which policies of folic 
acid fortiﬁ cation have already been implemented 
(ie, America, Australia, and New Zealand) or in which 
folate concentrations at the population level have been 
increasing in recent years.16,56 By contrast, around 40% of 
stroke events in the genetic studies that we analysed are 
from unfortiﬁ ed regions or populations with low 
concentrations of folate (Asia or Europe, low). Second, 
despite the extent of reduction in homocysteine 
concentrations being largely similar across the genetic 
studies and randomised trials (3·33 μmol/L for trials and 
2·58 μmol/L for large genetic studies), the length of 
follow-up was substantially diﬀ erent. Randomised trials 
had a weighted average follow-up of 4·7 years and 
allocation to the intervention occurred in middle age 
(mean age range 56–69 years). By contrast, genetic 
studies reﬂ ect lifetime exposure to the phenotype 
resulting from the genetic variant, since randomisation 
to the allele variants occurs at conception. Third, the 
number of stroke events in trials is substantially lower 
than that included in the genetic analyses (2314 stroke 
events in trials vs 20 885 events in genetic studies), thus 
the meta-analysis of randomised trials had fairly low 
statistical power to detect small beneﬁ ts or those noted 
mainly in a subgroup (eg, low folate regions). Fourth, 
evidence from randomised trials is derived mainly from 
individuals with established vascular disease, whereas 
that from genetic studies is mainly population-based. 
Therefore, genetic evidence should be regarded only as 
an approximate guide to the risk reduction that could be 
achieved by modiﬁ cation of homocysteine concentrations 
in randomised trials.
Although mendelian randomisation analysis reduces 
biases and confounding seen in non-genetic observational 
studies, it can still be prone to small-study bias and 
confounding by linkage disequilibrium. Our in-silico 
analysis evaluating the long-range linkage disequilibrium 
of the MTHFR 677C→T variant, used as an instrument 
for homocysteine, suggests that the diﬀ erential genetic 
results by folate regions are unlikely to arise by diﬀ erences 
in linkage disequilibrium between folate regions. To 
minimise the eﬀ ect of small-study bias, we made great 
eﬀ orts to rescue data from unpublished studies and 
undertook, at the analytical stage, several sensitivity 
analyses that attempted to quantify the eﬀ ect of small 
studies. First, restriction of the analysis to studies with at 
least 400 cases yielded an OR of 1·28 (95% CI 1·11 to 1·48; 
ﬁ gure 3). Second, taking into account the number and 
potential outcome of missing data in a trim-and-ﬁ ll 
analysis resulted in an adjusted summary OR of 1·30 
(95% CI 1·19 to 1·43; webappendix p 14). Finally, using 
the observed distribution of MTHFR C/T genotypes, we 
estimated that 41 additional null studies with 400 cases 
Panel: Research in context
Systematic review
Observational studies have shown an association between 
circulating concentrations of homocysteine and risk of stroke; 
however, these ﬁ ndings might arise from confounding or 
reverse causation, or both. Variants in MTHFR 677C→T 
(rs1801133), used as a non-confounded proxy of homocysteine 
exposure, have conﬁ rmed this association in previous 
meta-analysis; however, the magnitude of association diﬀ ered 
by geographical location. This ﬁ nding suggests that the 
association between homocysteine and stroke risk might be 
modiﬁ ed by prevailing folate intake, but another explanation 
could be small-study bias. Furthermore, ﬁ ndings from 
meta-analysis of randomised controlled trials investigating 
homocysteine-lowering interventions in stroke have been null.
Interpretation
The eﬀ ects of MTHFR 677C→T on homocysteine decreased as 
the prevailing level of folic acid increased. These eﬀ ects were 
mirrored in the analysis of MTHFR 677C→T and stroke: an 
association between MTHFR 677C→T and stroke was only 
evident in a region associated with low levels of folate, 
ﬁ ndings that were preserved in large studies. In regions with 
increasing levels of folate or with established policies of folic 
acid supplementation, the eﬀ ect of MTHFR 677C→T on 
stroke was null. These ﬁ ndings argue in favour of a 
gene–environment interaction. When we attempted to frame 
ﬁ ndings from MTHFR genetic studies within the context of 
homocysteine-lowering randomised trials evaluating risk of 
stroke, randomised trials were predominantly undertaken in 
regions with existing folic acid supplementation, which could 
potentially account for the null summary estimate of 
randomised trials, and hindered our comparison. Large 
genetic studies on stroke in regions with low folate levels are 
needed to conﬁ rm or refute our ﬁ ndings. If future trials of 
homocysteine-lowering interventions for stroke risk are to be 
undertaken, they should be set in low folate regions.
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and 400 controls each would be needed to reduce the 
overall OR from 1·68 to 1·15, the threshold OR at which 
cumulative evidence would be deemed questionable on 
the basis of Venice criteria39 (webappendix pp 4–5, 22). 
However, these analyses cannot wholly adjust for potential 
small-study bias19 and residual bias might persist, which 
emphasises the need for veriﬁ cation of the ﬁ ndings in 
large genetic studies undertaken in low folate regions.57
We used the MTHFR 677C→T variant as a genetic 
instrument to evaluate the eﬀ ects of homocysteine on 
disease risk; however, the poor speciﬁ city of this variant (a 
situation inherent for trans variants used as instruments 
of non-protein traits)58 makes it possible that the genetic 
eﬀ ect of MTHFR could be by a mechanism other than 
homocysteine.59 The use of probable folate status 
categories represents an estimate of population average 
with the possibility of substantial variability of natural 
folate intake within each category. This approach could 
underestimate the eﬀ ect of folate status categories on 
homocysteine concentration and stroke risk. By contrast, 
the use of categories of probable folate status instead of 
folate concentrations from individual participants creates 
the possibility that the eﬀ ect of the MTHFR variant by 
categories of population folate levels could be due to a 
strong association with another factor causally involved in 
the development of stroke. However, the plausibility of 
MTHFR–folic acid interaction is supported by the 
CARDIA study,60 which showed that the eﬀ ect of the 
MTHFR variant on homocysteine concentration is 
modiﬁ ed by participant folate concentrations, and that 
such eﬀ ect is largely diminished after the establishment 
of a policy of folic acid fortiﬁ cation. Finally, the eﬀ ect seen 
in low folate regions could be due to selective reporting 
bias in the subtype of stroke reported in genetic case-
control or cohort studies—ie, if stroke subtype was 
diﬀ erentially reported according to continent and was 
associated with MTHFR genotype, the observed signal 
could be inﬂ ated. In an attempt to minimise this bias, we 
contacted authors of all studies and asked for full details 
of all stroke subtypes, including unpublished data. 
Furthermore, when we examined the subtypes of stroke 
contributing to our main stroke outcome, there was 
general consistency in stroke subtype by folate region, 
with the exception of America, Australia, and New Zealand, 
mid (in which all strokes included were ischaemic). 
However, we cannot exclude the presence of selective 
outcome reporting bias that could aﬀ ect our results.
In conclusion, the concordance of ﬁ ndings on the 
genetic eﬀ ects of MTHFR on homocysteine concen-
trations and the genetic association with stroke risk 
argues in favour of eﬀ ect modiﬁ cation by prevailing 
folate concentrations in the population. If correct, this 
genetic ﬁ nding would have important repercussions for 
the interpretation of clinical trials of homocysteine-
lowering interventions. The eﬀ ect of homocysteine-
lowering interventions on stroke might be expected to be 
null in regions with high dietary folate intake or where 
food is fortiﬁ ed with folate, but it could be substantial in 
low folate regions such as Asia. Since stroke rates are 
high in Asian countries and the population at risk in 
Asia is very large, the public health beneﬁ t could be of 
great importance.61 Unfortunately, the evidence from 
randomised trials undertaken in low folate settings is 
scarce and genetic studies in the same settings have 
tended to be smaller than those in high folate settings, 
leaving a potential that estimates of the genetic eﬀ ect 
have been inﬂ ated.  To resolve uncertainty about whether 
the association of the MTHFR variant with stroke risk in 
Asian studies is a consequence of small-study bias, low 
folate consumption in that region, or both, a large 
genetic study of stroke in a low folate region would be 
needed.57 If further trials are to be done to evaluate the 
eﬃ  cacy of homocysteine-lowering interventions for 
stroke prevention, these should be undertaken in regions 
of low folate consumption. The ongoing China Stroke 
Primary Prevention Trial (CSPT)62 is investigating 
15 000 hypertensive individuals without established 
cardiovascular disease who are being randomly assigned 
to enalapril or enalapril plus folic acid and followed up 
for 5 years for development of the primary outcome, 
stroke. The addition of CSPT to the existing but small-
scale evidence from randomised trials in low folate 
regions should yield a more deﬁ nitive answer on the role 
(if any) of folic acid supplementation and lowering of 
homocysteine in prevention of stroke.
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